Icecure Medical Ltd Ord (ICCM)

$0.68 0.00 (-0.54%)
Market Cap 46.97M
Revenue (ttm) 3.29M
Net Income (ttm) -15.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -465.65%
Debt to Equity Ratio 0.00
Volume 219,400
Avg Vol 377,610
Day's Range N/A - N/A
Shares Out 68.70M
Stochastic %K 43%
Beta 0.29
Analysts Strong Sell
Price Target $3.05

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 623 0333
Fax: 972 4 623 0222
Address:
7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel
SuperBusa
SuperBusa Jan. 16 at 5:22 PM
$ICCM
0 · Reply
Joe_088
Joe_088 Jan. 16 at 5:07 PM
$VERO 👉👉 $ICCM
1 · Reply
StStephen72
StStephen72 Jan. 16 at 4:59 PM
$ICCM Took small starting position here. 1k at .675 2k at .69 Risk factors are Israel based AND currently Non-compliance on fillings. Pete
0 · Reply
Joe_088
Joe_088 Jan. 16 at 3:05 PM
$ICCM look at $VERO Patience is they key here
0 · Reply
Aimoney
Aimoney Jan. 15 at 11:15 PM
$IBRX To the moon $ICCM $IXHL
0 · Reply
thechad369
thechad369 Jan. 15 at 8:07 PM
$ICCM this volume is some of the lowest from a share price to volume perspective I've ever seen
0 · Reply
MahiMe
MahiMe Jan. 15 at 7:14 PM
$ICCM IceCure CEO Issues Letter to Shareholders https://www.sec.gov/Archives/edgar/data/1584371/000121390026003172/ea027250301ex99-1_icecure.htm. worth to read...
0 · Reply
MahiMe
MahiMe Jan. 15 at 7:06 PM
$ICCM IceCure Medical ($ICCM) remains highly bullish, driven by the recent FDA clearance and the start of new insurance reimbursement codes. Implied Upside: Approximately +355% from the current price (~$0.67). SUPER BULLISH...
0 · Reply
noonknight
noonknight Jan. 14 at 9:03 PM
$ICCM From Gemini AI: ProSense (manufactured by IceCure Medical Ltd., often referred to by its NASDAQ ticker ICCM) currently holds a CE mark, allowing it to be marketed and sold within the European Union. the system is approved in Europe for several indications, including the treatment of benign and malignant tumors in the breast, kidney, lung, and liver. The system has been CE marked for several years. It is widely used in Europe for gynecological indications (like abdominal wall endometriosis) and oncology. United States (FDA): In October 2025, ProSense achieved a major milestone by receiving FDA marketing authorization specifically for the local treatment of early-stage, low-risk breast cancer in women aged 70 and older. It was already FDA-cleared for other indications such as kidney and liver tumors. Global Presence: Besides the EU and U.S., the system also has regulatory approvals in other major markets, including China (under the brand name IceSense3) and Canada.
0 · Reply
grandpa_dirt
grandpa_dirt Jan. 14 at 4:25 PM
$ICCM Tried placing an order for 2000k more shares and Schwab responds with "Your order is not eligible for electronic entry." Anyone else have this issue?
3 · Reply
Latest News on ICCM
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

Jan 12, 2026, 8:30 AM EST - 4 days ago

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 17, 2025, 8:30 AM EST - 4 weeks ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Dec 10, 2025, 8:30 AM EST - 5 weeks ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Dec 5, 2025, 8:30 AM EST - 6 weeks ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript

Nov 19, 2025, 12:53 PM EST - 2 months ago

IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 19, 2025, 8:54 AM EST - 2 months ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 18, 2025, 8:30 AM EST - 2 months ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 14, 2025, 4:30 PM EST - 2 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 12, 2025, 8:30 AM EST - 2 months ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 10, 2025, 8:30 AM EST - 2 months ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Nov 3, 2025, 8:30 AM EST - 2 months ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 13, 2025, 8:30 AM EDT - 3 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 8:30 AM EDT - 3 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

IceCure Medical Ltd - Special Call

Oct 6, 2025, 11:25 AM EDT - 3 months ago

IceCure Medical Ltd - Special Call

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:28 PM EDT - 3 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Oct 3, 2025, 12:19 PM EDT - 3 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 30, 2025, 8:30 AM EDT - 3 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 4 months ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 18, 2025, 8:30 AM EDT - 4 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 15, 2025, 8:30 AM EDT - 4 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 8, 2025, 8:30 AM EDT - 4 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Sep 4, 2025, 8:30 AM EDT - 4 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 1:08 PM EDT - 5 months ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 13, 2025, 8:30 AM EDT - 5 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Aug 6, 2025, 8:30 AM EDT - 5 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 29, 2025, 9:00 AM EDT - 6 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 25, 2025, 9:00 AM EDT - 6 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 24, 2025, 9:00 AM EDT - 6 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

IceCure Announces Commencement of Rights Offering

Jul 10, 2025, 8:00 AM EDT - 6 months ago

IceCure Announces Commencement of Rights Offering

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jul 3, 2025, 8:30 AM EDT - 7 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 25, 2025, 9:23 AM EDT - 7 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

Jun 9, 2025, 8:30 AM EDT - 7 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 4:26 PM EDT - 8 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

IceCure Medical Reports First Quarter 2025 Financial Results

May 28, 2025, 8:30 AM EDT - 8 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 21, 2025, 8:30 AM EDT - 8 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

May 6, 2025, 8:30 AM EDT - 9 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 30, 2025, 8:30 AM EDT - 9 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 28, 2025, 8:30 AM EDT - 9 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Apr 22, 2025, 8:30 AM EDT - 9 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 1:45 PM EDT - 10 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 27, 2025, 8:30 AM EDT - 10 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 24, 2025, 8:30 AM EDT - 10 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 21, 2025, 8:30 AM EDT - 10 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 20, 2025, 8:30 AM EDT - 10 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 18, 2025, 8:30 AM EDT - 10 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Mar 17, 2025, 8:30 AM EDT - 10 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

Mar 10, 2025, 8:30 AM EDT - 11 months ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Feb 24, 2025, 8:30 AM EST - 11 months ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

Feb 4, 2025, 8:30 AM EST - 1 year ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Jan 27, 2025, 8:30 AM EST - 1 year ago

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

SuperBusa
SuperBusa Jan. 16 at 5:22 PM
$ICCM
0 · Reply
Joe_088
Joe_088 Jan. 16 at 5:07 PM
$VERO 👉👉 $ICCM
1 · Reply
StStephen72
StStephen72 Jan. 16 at 4:59 PM
$ICCM Took small starting position here. 1k at .675 2k at .69 Risk factors are Israel based AND currently Non-compliance on fillings. Pete
0 · Reply
Joe_088
Joe_088 Jan. 16 at 3:05 PM
$ICCM look at $VERO Patience is they key here
0 · Reply
Aimoney
Aimoney Jan. 15 at 11:15 PM
$IBRX To the moon $ICCM $IXHL
0 · Reply
thechad369
thechad369 Jan. 15 at 8:07 PM
$ICCM this volume is some of the lowest from a share price to volume perspective I've ever seen
0 · Reply
MahiMe
MahiMe Jan. 15 at 7:14 PM
$ICCM IceCure CEO Issues Letter to Shareholders https://www.sec.gov/Archives/edgar/data/1584371/000121390026003172/ea027250301ex99-1_icecure.htm. worth to read...
0 · Reply
MahiMe
MahiMe Jan. 15 at 7:06 PM
$ICCM IceCure Medical ($ICCM) remains highly bullish, driven by the recent FDA clearance and the start of new insurance reimbursement codes. Implied Upside: Approximately +355% from the current price (~$0.67). SUPER BULLISH...
0 · Reply
noonknight
noonknight Jan. 14 at 9:03 PM
$ICCM From Gemini AI: ProSense (manufactured by IceCure Medical Ltd., often referred to by its NASDAQ ticker ICCM) currently holds a CE mark, allowing it to be marketed and sold within the European Union. the system is approved in Europe for several indications, including the treatment of benign and malignant tumors in the breast, kidney, lung, and liver. The system has been CE marked for several years. It is widely used in Europe for gynecological indications (like abdominal wall endometriosis) and oncology. United States (FDA): In October 2025, ProSense achieved a major milestone by receiving FDA marketing authorization specifically for the local treatment of early-stage, low-risk breast cancer in women aged 70 and older. It was already FDA-cleared for other indications such as kidney and liver tumors. Global Presence: Besides the EU and U.S., the system also has regulatory approvals in other major markets, including China (under the brand name IceSense3) and Canada.
0 · Reply
grandpa_dirt
grandpa_dirt Jan. 14 at 4:25 PM
$ICCM Tried placing an order for 2000k more shares and Schwab responds with "Your order is not eligible for electronic entry." Anyone else have this issue?
3 · Reply
MahiMe
MahiMe Jan. 14 at 3:55 AM
$ICCM FDA marketing authorization granted for low-risk breast cancer in women aged 70+ Record ProSense® sales ~$3.4M for year ended Dec 31, 2025 Cash and cash equivalents ~$8.9M as of Dec 31, 2025 Record scientific visibility: 16 principal investigators presenting at 10 conferences Four new patents granted in the U.S. and China covering next-gen cryoablation tech CPT III reimbursement increased to $4,049 effective January 2026 https://finance.yahoo.com/news/icecure-ceo-issues-letter-shareholders-133000454.html
0 · Reply
Joe_088
Joe_088 Jan. 13 at 5:16 PM
Patience $ICCM Look at $XAIR
2 · Reply
SuperBusa
SuperBusa Jan. 13 at 3:20 PM
$ICCM
0 · Reply
Joe_088
Joe_088 Jan. 13 at 2:23 PM
$MBOT $ICCM my long hold 2026$$$
1 · Reply
VlaDracula
VlaDracula Jan. 12 at 7:44 PM
$ICCM needs to lower that age requirement to around 50 or 60 then we go moon
1 · Reply
SuperBusa
SuperBusa Jan. 12 at 7:32 PM
$ICCM
0 · Reply
Tonyboner
Tonyboner Jan. 12 at 7:04 PM
$ICCM
0 · Reply
Ericmao
Ericmao Jan. 12 at 3:05 PM
$ICCM I am quite disappointed about the prelim rev…. But the price movement very suspicious.
0 · Reply
PaulLaurent
PaulLaurent Jan. 12 at 1:34 PM
🕣 8:30am EST Watchlist udate $EVTV — Government POs headline; already +92% from our first alert with many scalps. Key level: $1.00 break/hold → watch VWAP reclaim and liquidity. $OSRH — Binding term sheet at affiliate Vaximm; event-driven tape. Look for volume build and prior HOD reclaims. $BDSX — Prelim Q4/FY25 update; watch for revenue cadence and margin color. Trade clean pivot reclaims. $PBM — 2026 strategy + board-approved buyback; monitor size/timing and borrow. Thin tape can rip. $ICCM — CEO letter highlights record Q4/FY25 ProSense momentum; scalp-first with tight risk on fades. Tone: Catalyst carry into the open—favor VWAP/pivot reclaims, trim into strength, and keep stops tight if volume thins.
2 · Reply
Planetpaprika
Planetpaprika Jan. 12 at 1:32 PM
$ICCM https://ir.icecure-medical.com/news-events/press-releases/detail/203/icecure-ceo-issues-letter-to-shareholders-reports-record-fourth-quarter-and-full-year-2025-prosense-sales
0 · Reply
grandpa_dirt
grandpa_dirt Jan. 12 at 1:21 PM
$ICCM jealous of the folks who got in at 60.00. I'm still 22% down. Hopefully once they show some sales growth we will be on the road to recovery. Then prosperity.
0 · Reply
Ericmao
Ericmao Jan. 12 at 8:46 AM
$ICCM will today be the big day ?
0 · Reply